DOI QR코드

DOI QR Code

Mechanistic Studies of Cyclin-Dependent Kinase Inhibitor 3 (CDKN3) in Colorectal Cancer

  • Yang, Cheng (Department of General Surgery, First Affiliated Hospital of Henan University of Science and Technology) ;
  • Sun, Jun-Jun (Department of General Surgery, First Affiliated Hospital of Henan University of Science and Technology)
  • Published : 2015.03.04

Abstract

Colorectal cancer is one of the most severe subtypes of cancer, and has the highest propensity to manifest as metastatic disease. Because of the lack of knowledge of events that correlate with tumor cell migration and invasion, few therapeutic options are available. The current study aimed to explore the mechanism of colorectal cancer in hope of identifying the ideal target for future treatment. We first discovered the pro-tumor effect of a controversial cell cycle regulator, cylin-dependent kinase inhibitor 3 (CDKN3), which is highly expressed in colorectal cancer, and the possible related signaling pathways, by bioinformatics tools. We found that CDKN3 had remarkable effects in suppressing colorectal cancer cell proliferation and migration, inducing cell cycle arrest and apoptosis in a colorectal cancer cell line, SW480 cells. Our study, for the first time, provided consistent evidence showing overexpression of cell cycle regulator CDKN3, in colorectal cancer. The in vitro studies in SW480 cells revealed a unique role of CDKN3 in regulating cellular behavior of colorectal cancer cells, and implied the possibility of targeting CDKN3 as a novel treatment for colorectal cancer.

Keywords

CDKN3;colorectal cancer;apoptosis;cancer cell migration

Acknowledgement

Supported by : Henan University of Science and Technology

References

  1. Deschoolmeester V, Baay M, Specenier P, et al (2010). A review of the most promising biomarkers in colorectal cancer: one step closer to targeted therapy. Oncologist, 15, 699-731. https://doi.org/10.1634/theoncologist.2010-0025
  2. Evan GI, Vousden KH (2001). Proliferation, cell cycle and apoptosis in cancer. Nature, 411, 342-8. https://doi.org/10.1038/35077213
  3. Fearon ER, Vogelstein B (1990). A genetic model for colorectal tumorigenesis. Cell, 61, 759-67. https://doi.org/10.1016/0092-8674(90)90186-I
  4. Hanahan D, Weinberg RA (2011). Hallmarks of cancer: the next generation. Cell, 144, 646-74. https://doi.org/10.1016/j.cell.2011.02.013
  5. Hannon GJ, Casso D, Beach D (1994). KAP: a dual specificity phosphatase that interacts with cyclin-dependent kinases. Proc Natl Acad Sci USA, 91, 1731-5. https://doi.org/10.1073/pnas.91.5.1731
  6. Ho A, Dowdy SF (2002). Regulation of G (1) cell-cycle progression by oncogenes and tumor suppressor genes. Curr Opin Genet Dev, 12, 47-52. https://doi.org/10.1016/S0959-437X(01)00263-5
  7. Lee SW, Reimer CL, Fang L, et al (2000). Overexpression of kinase-associated phosphatase (KAP) in breast and prostate cancer and inhibition of the transformed phenotype by antisense KAP expression. Mol Cell Biol, 20, 1723-32. https://doi.org/10.1128/MCB.20.5.1723-1732.2000
  8. Livak KJ, Schmittgen TD (2001). Analysis of relative gene expression data using real-time quantitative PCR and the 2 (-Delta Delta C (T)) Method. Methods, 25, 402-8. https://doi.org/10.1006/meth.2001.1262
  9. Niculescu MD, Yamamuro Y, Zeisel SH (2004). Choline availability modulates human neuroblastoma cell proliferation and alters the methylation of the promoter region of the cyclin-dependent kinase inhibitor 3 gene. J Neurochem, 89, 1252-9. https://doi.org/10.1111/j.1471-4159.2004.02414.x
  10. Orang AV, Barzegari A (2014). MicroRNAs in colorectal cancer: from diagnosis to targeted therapy. Asian Pac J Cancer Prev, 15, 6989-99. https://doi.org/10.7314/APJCP.2014.15.17.6989
  11. Pino MS, Chung DC (2010). The chromosomal instability pathway in colon cancer. Gastroenterology, 138, 2059-72. https://doi.org/10.1053/j.gastro.2009.12.065
  12. Poon RY, Hunter T (1995). Dephosphorylation of Cdk2 Thr160 by the cyclin-dependent kinase-interacting phosphatase KAP in the absence of cyclin. Science, 270, 90-3. https://doi.org/10.1126/science.270.5233.90
  13. Sherr CJ (2000). Cell cycle control and cancer. Harvey Lect, 96, 73-92.
  14. Sherr CJ, Roberts JM (1999). CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev, 13, 1501-12. https://doi.org/10.1101/gad.13.12.1501
  15. Siegel R, Desantis C, Jemal A (2014). Colorectal cancer statistics, 2014. CA Cancer J Clin, 64, 104-17. https://doi.org/10.3322/caac.21220
  16. Tamgue O, Chai CS, Hao L, et al (2013). Triptolide inhibits histone methyltransferase EZH2 and modulates the expression of its target genes in prostate cancer cells. Asian Pac J Cancer Prev, 14, 5663-9. https://doi.org/10.7314/APJCP.2013.14.10.5663
  17. Yeh CT, Lu SC, Chao CH, et al (2003). Abolishment of the interaction between cyclin-dependent kinase 2 and Cdkassociated protein phosphatase by a truncated KAP mutant. Biochem Biophys Res Commun, 305, 311-4. https://doi.org/10.1016/S0006-291X(03)00757-5
  18. Yeh CT, Lu SC, Chen TC, et al (2000). Aberrant transcripts of the cyclin-dependent kinase-associated protein phosphatase in hepatocellular carcinoma. Cancer Res, 60, 4697-700.
  19. Zheng ZX, Zheng RS, Zhang SW, et al (2014). Colorectal cancer incidence and mortality in China, 2010. Asian Pac J Cancer Prev, 15, 8455-60. https://doi.org/10.7314/APJCP.2014.15.19.8455

Cited by

  1. pathway is associated with Advanced Ovarian Cancer in Saudi Patients vol.16, pp.14, 2015, https://doi.org/10.7314/APJCP.2015.16.14.5807
  2. Integrated microRNA and mRNA Signature Associated with the Transition from the Locally Confined to the Metastasized Clear Cell Renal Cell Carcinoma Exemplified by miR-146-5p vol.11, pp.2, 2016, https://doi.org/10.1371/journal.pone.0148746